

## IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1. (Canceled)
2. (Currently amended) ~~Use according to~~ The method of claim ~~[[1]]~~ 9, wherein the concentration of rotigotine in the composition is at least 0.5 mg/ml.
3. (Currently amended) ~~Use according to~~ The method of claim ~~[[1]]~~ 9, wherein the concentration of rotigotine in the composition is 0.5 to 3 mg/ml.
4. (Currently amended) ~~Use according to~~ The method of claim ~~[[1]]~~ 9, wherein the at least one chloride salt is selected from NaCl, triethylammonium chloride and tributylammonium chloride.
5. (Currently amended) ~~Use according to~~ The method of claim 4, wherein the at least one chloride salt is triethylammonium chloride or tributylammonium chloride.
6. (Currently amended) ~~Use according to~~ The method of claim ~~[[1]]~~ 9, wherein the concentration of the chloride salt is 60 to 80 mmol/l.
7. (Currently amended) ~~Use according~~ The method of claim ~~[[1]]~~ 9, wherein the composition ~~is used in the~~ forms a donor phase of the iontophoretic device.
8. (Canceled)
9. (Currently amended) A method for the treatment of Parkinson's disease ~~characterised by~~ comprising applying a iontophoretic device, which comprises a composition comprising rotigotine and at least one chloride salt in a concentration of 1 to 140 mmol/l, the composition having a pH of 4 to 6.5, onto the skin of a patient in need thereof.
- 10–15. (Canceled)
16. (Currently amended) ~~Use according to~~ The method of Claim 7, wherein the composition ~~[[in]]~~ forming the donor phase of the iontophoretic device comprises

Serial No. 10/713,424

6102-000071/US

Amendment and Response to Office Action dated 23 March 2007 (Amendment B)  
July 19, 2007

rotigotine in a concentration of 0.5 to 3 mg/ml and at least one of triethylammonium chloride and tributylammonium chloride in a concentration of 60 to 80 mmol/l, **and** wherein the pH of the donor phase is 4.5 to 5.5.